How Does Skinoren Work in the Body
Chemical Composition, Mechanism of Action & Metabolic Effects Explained
Key Takeaways: How Skinoren Works
- Active Ingredient: Azelaic acid 20% w/w – a naturally occurring dicarboxylic acid with multiple anti‑acne actions.
- Triple Mechanism: Kills Cutibacterium acnes bacteria, normalises keratinocyte growth to unclog pores, and reduces inflammation.
- Onset & Duration: Visible improvement after 4 weeks; full benefit requires 2–4 months of regular use.
- Minimal Systemic Absorption: Less than 4% of applied azelaic acid enters the bloodstream, making it very safe for topical use.
- Metabolism & Excretion: Partially metabolised in the liver to shorter dicarboxylic acids; excreted primarily in urine.
Skinoren Cream contains 20% azelaic acid, a naturally occurring substance that targets the three main causes of acne: bacterial overgrowth, blocked pores, and inflammation. Understanding its precise mode of action helps patients appreciate why regular application leads to clearer skin.
Important Medical Advice
Do not apply Skinoren to broken skin, eyes, mouth, or other mucous membranes. If accidental contact occurs, rinse immediately with plenty of cool water. Discontinue use and seek medical advice if you experience severe local irritation or signs of an allergic reaction (rash, swelling, difficulty breathing).
Chemical Composition & Molecular Structure
Skinoren Cream contains 200 mg of azelaic acid per gram (20% w/w). Azelaic acid (C₉H₁₆O₄) is a straight‑chain saturated dicarboxylic acid with the systematic name nonanedioic acid. It naturally occurs in wheat, rye, and barley, and is also produced by the yeast Malassezia on human skin.
Structural Details
C₉H₁₆O₄
Two carboxyl groups (-COOH) at each end of a seven‑carbon aliphatic chain give azelaic acid its amphiphilic properties, allowing it to interact with both lipid membranes and aqueous environments.
pKa₁ = 4.55, pKa₂ = 5.33
LogP (octanol/water) = 1.23, indicating moderate lipophilicity. This enables good penetration of the stratum corneum and accumulation in the pilosebaceous unit.
Key Pharmaceutical Excipients
| Excipient | Function | Per Gram |
|---|---|---|
| Benzoic acid (E210) | Preservative | 125 mg |
| Propylene glycol | Humectant, penetration enhancer | 125 mg |
| Glycerol 85% | Moisturiser | – |
| Cetearyl octanoate + isopropyl myristate (PCL Liquid®) | Emollient, vehicle | – |
🗒️ Pharmaceutical insight: The cream base ensures optimal spreadability and controlled release of azelaic acid onto the skin, maximising local bioavailability while minimising systemic absorption.
Mechanism of Action: Azelaic Acid’s Triple Pathway
Azelaic acid exerts its anti‑acne effects through three complementary mechanisms:
- Antibacterial: Azelaic acid inhibits protein synthesis in Cutibacterium acnes (formerly Propionibacterium acnes) by interfering with mitochondrial function and bacterial NADH dehydrogenase. This reduces the bacterial load on the skin surface and within follicles.
- Normalisation of Keratinisation: It suppresses the proliferation of hyperproliferative keratinocytes and reduces the cohesion of follicular epithelial cells, preventing the formation of microcomedones and open/closed comedones.
- Anti‑inflammatory & Antioxidant: Azelaic acid scavenges reactive oxygen species (ROS) generated by neutrophils and keratinocytes, and reduces the release of pro‑inflammatory cytokines such as interleukin‑1β (IL‑1β) and tumour necrosis factor‑α (TNF‑α). This decreases erythema, pustule formation, and post‑inflammatory hyperpigmentation.
| Biological Target | Effect | Clinical Consequence |
|---|---|---|
| C. acnes bacteria | Bacteriostatic at concentrations ≥ 10 mM | Reduced inflammatory lesions |
| Keratinocytes | Reduced proliferation, normal desquamation | Fewer comedones, smoother skin |
| Neutrophils, macrophages | Inhibition of ROS and cytokine release | Decreased redness and swelling |
🗒️ Physiological insight: Unlike antibiotics, azelaic acid does not induce bacterial resistance, making it a valuable long‑term option for acne maintenance.
Absorption, Distribution & Penetration (Pharmacokinetics)
Following topical application, azelaic acid penetrates the stratum corneum and accumulates in the epidermis and pilosebaceous units. Systemic absorption is minimal – less than 4% of the applied dose enters the circulation. Peak plasma concentrations are low (approximately 100 ng/mL) and occur 2–3 hours after application. The drug does not accumulate with repeated use.
Skin Penetration
Due to its moderate lipophilicity, azelaic acid reaches therapeutic concentrations in the follicular infundibulum, where C. acnes resides and comedones form.
Distribution
Systemic distribution is negligible; the compound is primarily confined to the skin and does not cross the blood‑brain barrier or accumulate in deep tissues.
Metabolic Effects & Elimination
Azelaic acid undergoes partial oxidation in the liver via peroxisomal β‑oxidation, producing shorter dicarboxylic acids (suberic acid, pimelic acid) that are further metabolised to acetyl‑CoA and enter the Krebs cycle. The unchanged drug and its metabolites are excreted primarily in urine, with a small amount eliminated in faeces. The elimination half‑life after topical application is approximately 12 hours, consistent with the slow release from the skin depot.
⚠️ Metabolic caution: In patients with severe hepatic impairment, systemic exposure may be slightly increased, though clinical significance is minimal due to the low absorption. Always inform your doctor of any liver conditions.
Clinical Efficacy in Acne Management
Skinoren is indicated for the treatment of mild to moderate acne vulgaris in adults and adolescents aged 12 years and older. In clinical trials, twice‑daily application for 4 weeks resulted in a significant reduction in inflammatory lesions (papules and pustules) and a moderate reduction in non‑inflammatory lesions (comedones). Continued use for up to 6 months leads to sustained improvement with minimal risk of bacterial resistance.
A key advantage of azelaic acid is its ability to treat both inflammatory and comedonal acne simultaneously, while also improving post‑acne hyperpigmentation – a common concern in darker skin types. The European dermatology guidelines recommend azelaic acid as a first‑line topical agent for mild to moderate acne.
Skinoren FAQs
How long does Skinoren take to start working?
Most people notice an improvement after 4 weeks of regular use. Optimal results typically appear after 2 to 4 months of twice‑daily application.
Can Skinoren cause skin irritation?
Mild burning, redness, or itching may occur during the first week, especially if your skin is sensitive. These effects usually settle as your skin adapts. If severe, reduce to once daily or consult your doctor.
Is Skinoren safe to use during pregnancy?
Limited data suggest no known harm, but as a precaution, use only if clearly needed and after consulting your doctor. Avoid application on areas that may come into contact with the infant if breast‑feeding.
Can I use Skinoren with other acne treatments?
Yes, but avoid using with other topical medications on the same area unless directed by your doctor. Separate application times (e.g., morning and night) to reduce irritation.
Does Skinoren help with acne scars or dark spots?
Azelaic acid can fade post‑inflammatory hyperpigmentation by inhibiting melanocyte tyrosinase activity. It may also reduce the appearance of early scars by promoting normal skin turnover.
Need Skinoren with Professional Guidance?
If you have persistent acne and think Skinoren could help, a UK‑registered doctor can assess your skin and provide a prescription online.
Secure Prescription & Next‑Day Delivery
MHRA‑compliant | GPhC‑registered pharmacy | Discreet packaging | UK‑registered doctors
Start Acne ConsultationRelated Skinoren Guides
Clinical References & Sources
Medical Content Manager
Nabeel is a co-founder and medical content manager of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up‑to‑date.
Medical Doctor
Dr. Feroz is a GMC‑registered doctor and a medical reviewer at Chemist Doctor. He oversees acute condition and urgent care guidance.
Medical Director
Usman is a co‑founder and medical director of Chemist Doctor. He leads the organisation’s strategic vision, bridging clinical and operational priorities.
Review Date: 31 March 2026
Next Review: 30 September 2026
Published on: 31 March 2026
Last Updated: 31 March 2026